What is Boston Scientific Corp. Annual Revenue?

Boston Scientific Corp. Annual Revenue rose 17.61%, in the last year to $16,747 M. Its sector's average revenue growth for the last fiscal year was 8.57%.

What is Boston Scientific Corp. Annual Net Profit?

Boston Scientific Corp. Annual Net Profit rose 16.38% in the last year to $1,854 M. Its sector's average net profit growth for the last fiscal year was 4.36%.

What is Boston Scientific Corp. Price to Earning Ratio?

Boston Scientific Corp. Price to Earning Ratio is 74.75, higher than its sector PE ratio of 29.09.

What is Boston Scientific Corp. Stock Price?

Boston Scientific Corp. Stock Price rose 38.87% and outperformed its sector by 33.94% in the past year.

What is Boston Scientific Corp. Quarterly Revenue?

Boston Scientific Corp. Quarterly Revenue rose 22.44% YoY to $4,561 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

What is Boston Scientific Corp. Quarterly Net profit?

Boston Scientific Corp. Quarterly Net profit rose 12.08% YoY to $566 M. Its sector's average net profit growth YoY for the quarter was 32.89%.

What is Boston Scientific Corp. Debt to Equity Ratio?

Boston Scientific Corp. Debt to Equity Ratio of 0.51 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Boston Scientific Corp. Return on Equity(ROE)?

Boston Scientific Corp. Return on Equity(ROE) for the last financial year was 9.03%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Boston Scientific Corp. Mutual Fund Holding?

Boston Scientific Corp. Mutual Fund Holding decreased by 0.89% in the last quarter to 72.23.

What is Boston Scientific Corp. Promoter Share Holding?

Boston Scientific Corp. Promoter Share Holding increased by 0% in the most recent quarter to 0.17%.

What is Boston Scientific Corp. Interest Coverage Ratio?

Boston Scientific Corp. Interest Coverage Ratio is 8.48, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

What is Boston Scientific Corp. Institutional Holding?

Boston Scientific Corp. Institutional Holding increased by 0.28% in the last quarter to 92.95.

How is the Boston Scientific Corp. today?

The Boston Scientific Corp. today is trading in the down by -1.70% at 93.50.

How has Boston Scientific Corp. performed historically?

The Boston Scientific Corp. is currently trading down -1.70% on an intraday basis in the past week the index fell -0.18%. The index has been down -5.23% in the past quarter and rose 38.87% in the past year. You can view this in the overview section.

Boston Scientific Corp. XNYS: BSX

Boston Scientific Corp. Live Share Price Today, Share Analysis and Chart

Name: Boston Scientific Corp.: Is Infosys Ltd. worth buying?
Item: Boston Scientific Corp.
Rating: 2.024208375
Author: Trendlyne DVM scores

Expensive Performer

Download real time

93.50 -1.62 (-1.70%)

39.97% Gain from 52W Low

7.3M XNYS Volume

XNYS 21 Apr, 2025 3:46 PM (EDT)

Board Meeting

The next board meeting for Boston Scientific Corp. is on 02 May 2025 for the purpose of Boston Scientific Corp Annual General Meeting for 2025 See details

Boston Scientific Corp. Key Metrics

My Metrics

Select

Market Capitalization Market Leader Unavailable in chosen country	138,293.1
PE TTM High in industry Unavailable in chosen country	74.8
PEG TTM High in industry Unavailable in chosen country	4.6
Price to Book Below industry Median Unavailable in chosen country	6.4
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	93
Revenue Growth Qtr YoY % Market Leader Unavailable in chosen country	22.4
Operating Revenue growth TTM % Market Leader Unavailable in chosen country	17.6
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	12.1
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	16.1
Operating Profit Margin Qtr % Market Leader Unavailable in chosen country	17.3
Operating Profit Margin TTM % Market Runner Up Unavailable in chosen country	17.9
Piotroski Score Market Leader Unavailable in chosen country	7
Rel Perf vs Sector quarter% Unavailable in chosen country	4
ROE Annual % Below industry Median Unavailable in chosen country	9
RoA Annual % Below industry Median Unavailable in chosen country	5

All financials are in USD Million and price data in USD

Medium Financial Strength

50.0 / 100

Expensive Valuation

14.7 / 100

Technically Neutral

47.3 / 100

Expensive Performer These stocks are with medium quality and mid-range technical aspects. However, their financials make them little expensive so choose the right moment to buy them. View Similar Embed DVM

115

1Yr Price target upside is 23%

33 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Neutral Zone

58.0 % into P/E buy sell zone

Strong upside potential

% time spent below current P/E

Gains already realized

Boston Scientific Corp. Stock Price Analysis

Day Price Range -1.7% 1 Day return Unavailable in chosen country	93.5 (LTP) 92.795.2 LowHigh
Week Price Range -0.2% 1 Week return Unavailable in chosen country	93.5 (LTP) 92.796.7 LowHigh
Month Price Range -7.9% 1 Month return Unavailable in chosen country	93.5 (LTP) 86104.4 LowHigh
52 Week Price Range 38.9% 1 Year return Unavailable in chosen country	93.5 (LTP) 66.8107.2 LowHigh

View full Share Price History

Boston Scientific Corp. Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Boston Scientific Corp.'s Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

1.3

Avg. Estimate

1.9

Low Estimate

1.7

High Estimate

2.2

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 49.6% in FY25

Consensus Recommendation

34 ANALYST Recommendations

BUY

The consensus recommendation from 34 analysts for Boston Scientific Corp. is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Boston Scientific Corp. Stock Analysis

Boston Scientific Corp. stock analysis with key metrics, changes, and trends.

Boston Scientific Corp. Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$16,747 M	17.61%	positive	Annual Revenue rose 17.61%, in the last year to $16,747 M. Its sector's average revenue growth for the last fiscal year was 8.57%.
Annual Net Profit	$1,854 M	16.38%	positive	Annual Net Profit rose 16.38% in the last year to $1,854 M. Its sector's average net profit growth for the last fiscal year was 4.36%.
Price to Earning Ratio	74.75	-	negative	Price to Earning Ratio is 74.75, higher than its sector PE ratio of 29.09.
Stock Price	$93.50	38.87%	positive	Stock Price rose 38.87% and outperformed its sector by 33.94% in the past year.
Quarterly Revenue	$4,561 M	22.44%	positive	Quarterly Revenue rose 22.44% YoY to $4,561 M. Its sector's average revenue growth YoY for the quarter was 8.5%.
Quarterly Net profit	$566 M	12.08%	positive	Quarterly Net profit rose 12.08% YoY to $566 M. Its sector's average net profit growth YoY for the quarter was 32.89%.
Debt to Equity Ratio	0.51	-	positive	Debt to Equity Ratio of 0.51 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	9.03 %	9.03%	negative	Return on Equity(ROE) for the last financial year was 9.03%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	72.23 %	-0.89%	negative	Mutual Fund Holding decreased by 0.89% in the last quarter to 72.23.
Promoter Share Holding	0.17 %	0%	positive	Promoter Share Holding increased by 0% in the most recent quarter to 0.17%.
Interest Coverage Ratio	8.48	-	positive	Interest Coverage Ratio is 8.48, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
Institutional Holding	92.95 %	0.28%	positive	Institutional Holding increased by 0.28% in the last quarter to 92.95.

VIEW LESS

Loading data..

Boston Scientific Corp. - Company Profile

What does Boston Scientific Corp. do?

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Year

Boston Scientific Corp. Board of directors

All Gross Remunerations are in USD

Mr. Charles J. Dockendorff

Independent Director

2025

Gross Remuneration

Year

Boston Scientific Corp. Live Share Price Today, Share Analysis and Chart

39.97% Gain from 52W Low

Boston Scientific Corp. Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Boston Scientific Corp. Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Boston Scientific Corp. Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Boston Scientific Corp.'s Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

EPS is expected to grow by 49.6% in FY25

Consensus Recommendation

The consensus recommendation from 34 analysts for Boston Scientific Corp. is BUY

Boston Scientific Corp. Stock Analysis

Boston Scientific Corp. stock analysis with key metrics, changes, and trends.

Annual Revenue rose 17.61%, in the last year to $16,747 M. Its sector's average revenue growth for the last fiscal year was 8.57%.

Annual Net Profit rose 16.38% in the last year to $1,854 M. Its sector's average net profit growth for the last fiscal year was 4.36%.

Price to Earning Ratio is 74.75, higher than its sector PE ratio of 29.09.

Stock Price rose 38.87% and outperformed its sector by 33.94% in the past year.

Quarterly Revenue rose 22.44% YoY to $4,561 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

Quarterly Net profit rose 12.08% YoY to $566 M. Its sector's average net profit growth YoY for the quarter was 32.89%.

Debt to Equity Ratio of 0.51 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was 9.03%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.89% in the last quarter to 72.23.

Promoter Share Holding increased by 0% in the most recent quarter to 0.17%.

Interest Coverage Ratio is 8.48, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Institutional Holding increased by 0.28% in the last quarter to 92.95.

Boston Scientific Corp. - Company Profile

What does Boston Scientific Corp. do?

Boston Scientific Corp. Management structure

Mr. Michael F. Mahoney

Chairman of the Board, President and Chief Executive Officer

Mr. Daniel J. Brennan

Executive Vice President and Chief Financial Officer

Mr. Joseph M. Fitzgerald

Executive Vice President and Group President, Cardiology

Mr. Arthur C. Butcher

Executive Vice President and Group President, MedSurg and Asia Pacific

Mr. Jeffrey B. Mirviss

Executive Vice President and President, Peripheral Interventions

Mr. Jonathan R. Monson

Senior Vice President, Investor Relations

Boston Scientific Corp. Board of directors

Mr. Charles J. Dockendorff